FDA News

MHR Unveils FDA Approved Rezultz LaserComb, a New In-Home Drug-Free Treatment

(March 15, 2007)--Medical Hair Restoration's (MHR) new Rezultz LaserComb is poised to revolutionize the hair growth industry as the only FDA-approved, drug-free alternative for an estimated 55 million men in the U.S. suffering from hair loss. Extensive clinical studies, under the direction of MHR founder Dr. Matt Leavitt, concluded that 93% of participants (ages 30-60) using the LaserComb had an increase in the number of terminal (thick) hairs over a six-month period. The LaserComb is an affordable and convenient, hand-held laser device that can be used in the privacy of a patient's home and produces noticeable results with 10-15 minute treatments, three times per week.

States Dr. Matt Leavitt, Founder and Medical Director of MHR, "The Rezultz LaserComb is a medical breakthrough that will bring tremendous relief to men of all ages suffering from hair loss. I am impressed with the protocol and results from the clinical trials that Lexington International, LLC (manufacturer and innovator of the LaserComb technology) has conducted. With the FDA clearing the LaserComb as a medical device, it offers a very attractive hair growth option for medical practitioners. We can now deliver a new modality to our patients and achieve strong user satisfaction."

Using effective low level laser therapy (LLLT), the LaserComb improves the appearance of hair by increasing blood flow to the scalp and hair follicles to promote thickness and growth. The unique laser light penetrates into the scalp tissue where it stimulates micro-circulation and improves cellular metabolism and protein synthesis. The LaserComb offers an affordable, convenient home- care regimen effective when combined with hair transplantation and on its own.

MHR offers the Rezultz LaserComb as one of many medically accepted options for hair growth, including hair transplantation, Laser Hair Therapy, Propecia, FreeGaine and Rezultz Hair Care for Thinning Hair.

Share or bookmarklet this web page at: